Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Atsushi Ogata, Yasuhiro Kato, Shinji Higa & Keiji Maeda. (2019) Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. Expert Opinion on Drug Delivery 16:6, pages 639-648.
Read now
Read now
Jéssica Barreto Ribeiro dos Santos, Augusto Afonso Guerra Junior, Michael Ruberson Ribeiro da Silva, Alessandra Maciel Almeida, Francisco de Assis Acurcio & Juliana Alvares-Teodoro. (2019) First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert Review of Clinical Pharmacology 12:4, pages 363-370.
Read now
Read now
Atsushi Ogata, Yasuhiro Kato, Shinji Higa & Kazuyuki Yoshizaki. (2019) IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Modern Rheumatology 29:2, pages 258-267.
Read now
Read now
Alberto Migliore, Emanuele Bizzi, Colin Gerard Egan, Mauro Bernardi & Lea Petrella. (2015) Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. Therapeutics and Clinical Risk Management 11, pages 1325-1335.
Read now
Read now
Toshio Tanaka, Yoshihiro Hishitani & Atsushi Ogata. (2014) Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics: Targets and Therapy 8, pages 141-153.
Read now
Read now
Andreas M Reimold. (2012) The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatology: Research and Reviews 4, pages 33-47.
Read now
Read now
Articles from other publishers (27)
Anita Patel, Margaret Heslin, David L. Scott, Dominic Stringer, Fraser Birrell & Fowzia Ibrahim. (2020) Cost‐Effectiveness of Combination Disease‐Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial. Arthritis Care & Research 72:3, pages 334-342.
Crossref
Crossref
Jae-hyuck Shim, Zheni Stavre & Ellen M. Gravallese. (2017) Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications. Calcified Tissue International 102:5, pages 533-546.
Crossref
Crossref
Miyoung Choi, Min Kyung Hyun, Seongmi Choi, Ha Jin Tchoe, Sung Yeon Lee, Kyeong Min Son, Min-Jeong Kim, Young Ok Jung & Hyun Ah Kim. (2017) Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison. The Korean Journal of Internal Medicine 32:3, pages 536-547.
Crossref
Crossref
Evelien Bergrath, Robert A. Gerber, David Gruben, Tatjana Lukic, Charles Makin & Gene Wallenstein. (2017) Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. International Journal of Rheumatology 2017, pages 1-15.
Crossref
Crossref
Maria-Cecilia Vieira, Samuel H. Zwillich, Jeroen P. Jansen, Brielan Smiechowski, Dean Spurden & Gene V. Wallenstein. (2016) Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. Clinical Therapeutics 38:12, pages 2628-2641.e5.
Crossref
Crossref
Jéssica Barreto Ribeiro dos Santos, Alessandra Maciel Almeida, Francisco de Assis Acurcio, Haliton Alves de Oliveira Junior, Adriana Maria Kakehasi, Augusto Afonso Guerra Junior, Marion Bennie, Brian Godman & Juliana Alvares. (2016) Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. Journal of Comparative Effectiveness Research 5:6, pages 539-549.
Crossref
Crossref
Sarah L. Field, Tathagata Dasgupta, Michele Cummings, Richard S. Savage, Julius Adebayo, Hema McSara, Jeremy Gunawardena & Nicolas M. Orsi. (2015) Bayesian modeling suggests that IL-12 (p40), IL-13 and MCP-1 drive murine cytokine networks in vivo. BMC Systems Biology 9:1.
Crossref
Crossref
Evangelia Zampeli, Panayiotis G. Vlachoyiannopoulos & Athanasios G. Tzioufas. (2015) Treatment of rheumatoid arthritis: Unraveling the conundrum. Journal of Autoimmunity 65, pages 1-18.
Crossref
Crossref
Anton Wulf Christensen, Simon Tarp, Daniel E. Furst, Anna D?ssing, Kirstine Amris, Henning Bliddal, Peter C. Taylor & Robin Christensen. (2015) Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study. PLOS ONE 10:9, pages e0136982.
Crossref
Crossref
Ingunn Fride Tvete, Bent Natvig, J?rund G?semyr, Nils Meland, Marianne R?ine & Marianne Klemp. (2015) Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. PLOS ONE 10:9, pages e0137258.
Crossref
Crossref
Vasco C. Romão, Maria José Santos, Joaquim Polido-Pereira, Cátia Duarte, Patrícia Nero, Cláudia Miguel, José António Costa, Miguel Bernardes, Fernando M. Pimentel-Santos, Filipe Barcelos, Lúcia Costa, José António Melo Gomes, José Alberto Pereira da Silva, Jaime Cunha Branco, José Canas da Silva, José António Pereira da Silva, João Eurico Fonseca & Helena Canhão. (2015) Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. BioMed Research International 2015, pages 1-13.
Crossref
Crossref
Giuseppe Lopalco, Luca Cantarini, Antonio Vitale, Florenzo Iannone, Maria Grazia Anelli, Laura Andreozzi, Giovanni Lapadula, Mauro Galeazzi & Donato Rigante. (2015) Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. Mediators of Inflammation 2015, pages 1-21.
Crossref
Crossref
Jeroen P Jansen, Felicity Buckley, Fred Dejonckheere & Sarika Ogale. (2014) Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis. Health and Quality of Life Outcomes 12:1.
Crossref
Crossref
Ferr?n Catal?-L?pez, Aurelio Tob?as, Chris Cameron, David Moher & Brian Hutton. (2014) Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatology International 34:11, pages 1489-1496.
Crossref
Crossref
Niels Graudal, Thorbj?rn Hubeck-Graudal, Simon Tarp, Robin Christensen & Gesche J?rgens. (2014) Effect of Combination Therapy on Joint Destruction in Rheumatoid Arthritis: A Network Meta-Analysis of Randomized Controlled Trials. PLoS ONE 9:9, pages e106408.
Crossref
Crossref
Steve Kanters, Eric Druyts, Edward J. Mills & Kristian Thorlund. (2014) What drives the comparative effectiveness of biologics vs methotrexate in rheumatoid arthritis? Meta-regression and graphical inspection of suspected clinical factors. Rheumatology 53:7, pages 1264-1273.
Crossref
Crossref
Petra Baji, Márta Péntek, László Czirják, Zoltán Szekanecz, György Nagy, László Gulácsi & Valentin Brodszky. (2014) Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. The European Journal of Health Economics 15:S1, pages 53-64.
Crossref
Crossref
Eugeniusz J. Kucharz. (2014) How compare biologics applied for rheumatic disorders?. Rheumatology 52:2, pages 112-119.
Crossref
Crossref
Charles Anthony Dinarello. (2014) An Expanding Role for Interleukin-1 Blockade from Gout to Cancer. Molecular Medicine 20:S1, pages S43-S58.
Crossref
Crossref
Charles A. Dinarello & Jos W.M. van der Meer. (2013) Treating inflammation by blocking interleukin-1 in humans. Seminars in Immunology 25:6, pages 469-484.
Crossref
Crossref
Marieke H Otten, Janneke Anink, Sandra Spronk & Lisette W A van Suijlekom-Smit. (2013) Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Annals of the Rheumatic Diseases 72:11, pages 1806-1812.
Crossref
Crossref
Florian MP Meier, Marc Frerix, Walter HermannUlf Müller-Ladner. (2013) Current immunotherapy in rheumatoid arthritis. Immunotherapy 5:9, pages 955-974.
Crossref
Crossref
Kristian Thorlund, Eric Druyts, J Antonio Aviña-Zubieta, Ping Wu & Edward J Mills. (2013) Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Annals of the Rheumatic Diseases 72:9, pages 1524-1535.
Crossref
Crossref
Laura Marcela Rojas Díaz, Héctor Mauricio Pérez Quevedo, Paul Alejandro Mendez Patarroyo, Paola Coral Alvarado, Rafael Alfonso-Cristancho & Gerardo Quintana. (2013) Comparaciones indirectas: una herramienta para la toma de decisiones en salud. Revista Colombiana de Reumatología 20:3, pages 128-140.
Crossref
Crossref
Susanne Schmitz, Roisin Adams & Cathal Walsh. (2013) Incorporating data from various trial designs into a mixed treatment comparison model. Statistics in Medicine 32:17, pages 2935-2949.
Crossref
Crossref
Brad Bolon. (2011) Cellular and Molecular Mechanisms of Autoimmune Disease. Toxicologic Pathology 40:2, pages 216-229.
Crossref
Crossref
Atsushi OgataToru HiranoYoshihiro HishitaniToshio Tanaka. (2012) Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 5, pages CMAMD.S7371.
Crossref
Crossref